Another study has been published suggesting that patients taking semaglutide—the active ingredient in Novo Nordisk’s blockbuster drug Ozempic—may face a higher risk of developing a rare eye condition that can lead to blindness.
“The glucagon-like peptide 1 receptor agonist (GLP-1RA) semaglutide has quickly become a key treatment for managing type 2 diabetes and obesity. Recent findings have raised concern about a potential association between semaglutide use and non-arteritic anterior ischemic optic neuropathy (NAION),” according to a new Danish–Norwegian study, backing up similar results from a Harvard University study published in July.
Non-arteritic anterior ischemic optic neuropathy, or NAION, occurs when blood flow to the optic nerve is blocked, causing sudden vision loss.
Bloomberg first reported the results on Friday afternoon. The findings were initially published on Wednesday on medRxiv, an online platform for sharing research.
The results indicate that a type 2 diabetes patient taking Ozempic for two decades would have a .3% to .5% chance of developing NAION. […]
— Read More: www.zerohedge.com
